Johnson & Johnson logo

Johnson & Johnson (JNJ)

Market Closed
16 Dec, 16:29
XFRA XFRA
179. 20
-2.76
-1.52%
- Market Cap
29.06 P/E Ratio
4.96% Div Yield
1,316 Volume
9.91 Eps
181.96
Previous Close
Day Range
179.08 183.96
Year Range
128.16 183.96
Want to track JNJ and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Earnings results expected in 35 days

Summary

JNJ closed today lower at €179.2, a decrease of 1.52% from yesterday's close, completing a monthly increase of 0.28% or €0.5. Over the past 12 months, JNJ stock gained 27.4%.
JNJ pays dividends to its shareholders, with the most recent payment made on Dec 09, 2025. The next estimated payment will be in In 2 months on Mar 09, 2026 for a total of €1.12384.
The last earnings report, released on Oct 14, 2025, missed the consensus estimates by -2.76%. On average, the company has fell short of earnings expectations by -1.05%, based on the last three reports. The next scheduled earnings report is due on Jan 20, 2026.
Johnson & Johnson has completed 6 stock splits, with the recent split occurring on Jun 13, 2001.
The company's stock is traded on 19 different exchanges and in various currencies, with the primary listing on NYSE (USD).

JNJ Chart

Final Trade: JNJ, NVO, UBER, BMY

Final Trade: JNJ, NVO, UBER, BMY

The final trades of the day with CNBC's Melissa Lee and the 'Fast Money' traders.

Youtube | 1 day ago
FDA Approves J&J's Akeega for Expanded Use in Prostate Cancer

FDA Approves J&J's Akeega for Expanded Use in Prostate Cancer

JNJ secures FDA approval to expand Akeega into earlier-stage prostate cancer, backed by strong phase III data and a first-of-its-kind precision combo.

Zacks | 1 day ago
Johnson & Johnson (JNJ) Is Considered a Good Investment by Brokers: Is That True?

Johnson & Johnson (JNJ) Is Considered a Good Investment by Brokers: Is That True?

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?

Zacks | 1 day ago

Johnson & Johnson (JNJ) FAQ

What is the stock price today?

The current price is €179.20.

On which exchange is it traded?

Johnson & Johnson is listed on NYSE.

What is its stock symbol?

The ticker symbol is JNJ.

Does it pay dividends? What is the current yield?

Yes, It pays dividends and the current yield is 4.96%.

What is its market cap?

As of today, no market cap data is available.

When is the next earnings date?

The next earnings report will release on Jan 20, 2026.

Has Johnson & Johnson ever had a stock split?

Johnson & Johnson had 6 splits and the recent split was on Jun 13, 2001.

Johnson & Johnson Profile

Media Industry
Communication Services Sector
Joaquin Duato CEO
XFRA Exchange
US4781601046 ISIN
US Country
138,100 Employees
25 Nov 2025 Last Dividend
13 Jun 2001 Last Split
- IPO Date

Overview

Johnson & Johnson, a renowned entity in the healthcare sector, operates globally with a broad focus on research, development, manufacturing, and sales of healthcare products. The company is structured in multiple segments, primarily Innovative Medicine and MedTech, catering to a vast array of therapeutic areas and medical needs. Founded in 1886, the company is headquartered in New Brunswick, New Jersey, illustrating a longstanding presence and commitment to healthcare innovation and advancement. Through its extensive product line and diversified service offerings, Johnson & Johnson reaches a wide audience, including retailers, wholesalers, distributors, hospitals, and healthcare professionals, providing prescription and non-prescription products alike.

Products and Services

The company's portfolio is divided into two main segments, each encompassing a variety of products and services designed to meet the complex demands of modern healthcare:

  • Innovative Medicine:

    This segment includes a range of products for different therapeutic areas. These encompass immunology (covering diseases like rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis), infectious diseases (including HIV/AIDS treatment), neuroscience (targeting mood disorders, neurodegenerative disorders, schizophrenia), oncology (focused on cancers such as prostate, lung, bladder, and hematologic malignancies), cardiovascular and metabolism (addressing conditions like thrombosis, diabetes, and macular degeneration), and pulmonary hypertension, specifically pulmonary arterial hypertension.

  • MedTech:

    This segment offers products and technologies across a range of medical fields. Interventional Solutions include electrophysiology products for heart rhythm disorders and technologies for severe coronary artery disease treatment. The neurovascular care line focuses on treating hemorrhagic and ischemic strokes. Orthopaedics products support treatments for hips, knees, trauma, spine, and sports injuries. The surgery portfolio covers advanced and general surgery technologies and solutions for breast aesthetics and ear, nose, and throat procedures. Additionally, MedTech offers visual health products like ACUVUE Brand contact lenses and TECNIS intraocular lenses for cataract surgery.

Contact Information

Address: One Johnson & Johnson Plaza
Phone: 732 524 0400